Prognostic effect of coexisting TP53 and ZFHX3 mutations in non‐small cell lung cancer patients treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic effect of coexisting TP53 and ZFHX3 mutations in non‐small cell lung cancer patients treated with immune checkpoint inhibitors

Published:2021-06-13 Issue:3 Volume:94 Page:
ISSN:0300-9475
Container-title:Scandinavian Journal of Immunology
language:en
Short-container-title:Scand J Immunol

Author:

Zhang Lijuan¹,Zhang Tongyan²,Shang Bin²,Li Yaqiong³,Cao Zhixin³,Wang Hui²^ORCID

Affiliation:

1. Department of Pediatric Surgery Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

2. Department of Thoracic Surgery Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

3. Department of Pathology Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

Publisher

Wiley

Subject

Immunology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.13087

Reference38 articles.

1. Global cancer statistics, 2012

2. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

5. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer;Clinical Lung Cancer;2024-07

2. Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer;Pharmaceutics;2023-06-21

3. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations;Journal of Cancer Research and Clinical Oncology;2023-06-01

4. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer;Frontiers in Pharmacology;2023-02-15

5. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer;Cancer Medicine;2022-11-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3